(R)-diperodon | 440351-37-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-diperodon
• 英文别名: Diperodon anhydrous, (R)-；[(2R)-2-(phenylcarbamoyloxy)-3-piperidin-1-ylpropyl] N-phenylcarbamate
• CAS: 440351-37-1
• 化学式: C₂₂H₂₇N₃O₄
• 分子量: 397.474
• InChiKey: YUGZHQHSNYIFLG-HXUWFJFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  79.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  狄帕洛东 在 quinine combined per(3,5-dimethyl)phenylcarbamoylated- β-CD on silica surface 作用下， 以 甲醇 为溶剂， 生成 (R)-diperodon 、 (S)-diperodon
  参考文献：
  名称：

  A quasi-dual-chiral-channel specific enantioseparation material

  摘要：

  DOI：

  10.1016/j.cclet.2023.108342

文献信息

• [EN] THERAPEUTIC ACRYLATES AS ENHANCED MEDICAL ADHESIVES<br/>[FR] ACRYLATES THÉRAPEUTIQUES UTILES EN TANT QU'ADHÉSIFS MÉDICAUX AMÉLIORÉS
  申请人：UNIV CARNEGIE MELLON

  公开号：WO2018052936A1

  公开（公告）日：2018-03-22

  Provided herein are therapeutic acrylate compounds useful as medical adhesives, comprising a therapeutic agent covalently linked to a methacrylate or cyanoacrylate moiety. Adhesive compositions and kits, such as liquid sutures and bone cement also are provided along with uses for the compositions.

  本文提供了作为医用粘合剂有用的治疗丙烯酸酯化合物，包括与甲基丙烯酸酯或氰丙烯酸酯基团共价连接的治疗剂。此外还提供了粘合剂组合物和套件，如液体缝合线和骨水泥，以及这些组合物的用途。
• [EN] PYRROLOPYRIDINE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS<br/>[FR] COMPOSÉS PYRROLOPYRIDINE-ANILINE DESTINÉS AU TRAITEMENT D'AFFECTIONS DE LA PEAU
  申请人：NFLECTION THERAPEUTICS INC

  公开号：WO2018213810A1

  公开（公告）日：2018-11-22

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X1, R1, R2, R2a, R3, R3a, and R3b are as described herein.

  本文提供了化合物、包含这些化合物的药物组合物、制备这些化合物的方法，以及在需要MEK抑制剂的受试者中治疗疾病或障碍的方法和使用这些化合物和组合物的方法，其中该化合物符合公式（I），其中X1、R1、R2、R2a、R3、R3a和R3b如本文所述。
• [EN] 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN<br/>[FR] SAXITOXINES 11,13-MODIFIÉES DESTINÉES AU TRAITEMENT DE LA DOULEUR
  申请人：SITEONE THERAPEUTICS INC

  公开号：WO2018183781A1

  公开（公告）日：2018-10-04

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): where R4, R4a, R7, R7a, and X2 are as described herein.

  提供的是化合物、包含该化合物的药物组合物、制备该化合物的方法，以及使用该化合物和组合物治疗与电压门控钠通道功能相关的病症的方法，其中所述化合物是根据公式(I)的11,13-修饰的石房蛤毒素：其中R4、R4a、R7、R7a和X2如本文所述。
• [EN] 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN<br/>[FR] SAXITOXINES MODIFIÉES 11,13 POUR LE TRAITEMENT DE LA DOULEUR
  申请人：SITEONE THERAPEUTICS INC

  公开号：WO2020072835A1

  公开（公告）日：2020-04-09

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-gated sodium channel function where the compounds are 11,13-modified saxitoxins according to Formula (I): (Formula (I)); where R1, and R2 are as described herein.

  本文提供了化合物、包含该化合物的药物组合物、制备该化合物的方法，以及在治疗与电压门控钠通道功能相关的疾病中使用该化合物和组合物的方法，其中该化合物是根据式(I)的11,13-修饰沙雌毒素：(式(I))；其中R1和R2如本文所述。
• Crosslinked hyaluronic acid compositions for tissue augmentation
  申请人：Sadozai K. Khalid

  公开号：US20050136122A1

  公开（公告）日：2005-06-23

  A hyaluronic acid (HA) composition includes crosslinked, water-insoluble, hydrated HA gel particles. The HA includes crosslinks represented by the following structural formula: HA—U—R 2 —U—HA The variables are defined herein. A method of augmenting tissue in a subject includes inserting a needle into a subject at a location in the subject that is in need of tissue augmentation, wherein the needle is coupled to a syringe loaded with the HA composition, and applying force to the syringe, to deliver the HA composition into the subject. A method of preparing the HA composition, includes forming water-insoluble, dehydrated crosslinked HA particles, separating the water-insoluble, dehydrated particles by average diameter, selecting a subset of particles by average diameter, and hydrating the subset of dehydrated particles with a physiologically compatible aqueous solution. Another method of preparing the crosslinked HA composition includes crosslinking a precursor of the crosslinked HA with a biscarbodiimide in the presence of a pH buffer and dehydrating the crosslinked HA. Also included is a method of augmenting tissue in a subject that is in need of tissue augmentation. A method of stabilizing crosslinked HA includes hydrating water-insoluble, dehydrated crosslinked HA with a physiologically compatible aqueous solution that includes a local anesthetic, wherein the value of storage modulus G′ for the stabilized composition is at least about 110% of the value of G′ for a non-stabilized composition,. Also included is the stabilized HA composition.

  一种透明质酸（HA）组合物包括交联的、不溶于水的、水合的HA凝胶颗粒。HA包括由以下结构式表示的交联：HA—U—R2—U—HA。变量在此定义。一种在受试者中增强组织的方法包括将针插入受试者体内需要组织增强的位置，其中针连接到装有HA组合物的注射器，并施加力量到注射器，将HA组合物注入受试者体内。一种制备HA组合物的方法包括形成不溶于水的、脱水的交联HA颗粒，通过平均直径分离不溶于水的、脱水的颗粒，通过平均直径选择颗粒的子集，并用生理兼容的水溶液使脱水的颗粒子集水化。另一种制备交联HA组合物的方法包括在pH缓冲剂存在下用双异氰酸酯交联交联HA的前体，并脱水交联HA。还包括一种在需要组织增强的受试者中增强组织的方法。一种稳定交联HA的方法包括用含有局部麻醉剂的生理兼容水溶液水化不溶于水的、脱水的交联HA，其中稳定组合物的存储模量G′的值至少为非稳定组合物G′值的约110%。还包括稳定的HA组合物。